AU2023210279A1 - 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors - Google Patents
1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors Download PDFInfo
- Publication number
- AU2023210279A1 AU2023210279A1 AU2023210279A AU2023210279A AU2023210279A1 AU 2023210279 A1 AU2023210279 A1 AU 2023210279A1 AU 2023210279 A AU2023210279 A AU 2023210279A AU 2023210279 A AU2023210279 A AU 2023210279A AU 2023210279 A1 AU2023210279 A1 AU 2023210279A1
- Authority
- AU
- Australia
- Prior art keywords
- dimethyl
- pyrrolo
- pyrido
- dihydro
- pyrazino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267018P | 2022-01-21 | 2022-01-21 | |
| US63/267,018 | 2022-01-21 | ||
| PCT/US2023/060944 WO2023141536A1 (en) | 2022-01-21 | 2023-01-20 | 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023210279A1 true AU2023210279A1 (en) | 2024-05-23 |
Family
ID=85382827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023210279A Pending AU2023210279A1 (en) | 2022-01-21 | 2023-01-20 | 1,3,4,7-tetrahydro-2h-pyrrolo [3',2':5,6] pyrido[2,3-b] [1,4] oxazepine bc1-2 inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11964990B2 (https=) |
| EP (1) | EP4466273A1 (https=) |
| JP (2) | JP7714811B2 (https=) |
| KR (1) | KR20240136972A (https=) |
| CN (1) | CN119053610A (https=) |
| AR (1) | AR128310A1 (https=) |
| AU (1) | AU2023210279A1 (https=) |
| CA (1) | CA3242074A1 (https=) |
| CO (1) | CO2024009334A2 (https=) |
| IL (1) | IL312709A (https=) |
| MX (1) | MX2024008840A (https=) |
| TW (1) | TW202340210A (https=) |
| WO (1) | WO2023141536A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11964990B2 (en) * | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
| CN117820134A (zh) * | 2024-01-10 | 2024-04-05 | 山东盛安贝新材料有限公司南京分公司 | 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018322059C1 (en) | 2017-08-23 | 2024-09-12 | Guangzhou Lupeng Pharmaceutical Company Ltd. | BCL-2 inhibitors |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| KR20220158725A (ko) | 2020-02-24 | 2022-12-01 | 광조우 루펭 파마슈티칼 컴퍼니 엘티디. | Bcl2 억제제를 함유하는 핫 멜트 압출 고체 분산체 |
| US11964990B2 (en) * | 2022-01-21 | 2024-04-23 | Abbvie Inc. | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors |
-
2023
- 2023-01-19 US US18/156,987 patent/US11964990B2/en active Active
- 2023-01-19 TW TW112102814A patent/TW202340210A/zh unknown
- 2023-01-20 AU AU2023210279A patent/AU2023210279A1/en active Pending
- 2023-01-20 WO PCT/US2023/060944 patent/WO2023141536A1/en not_active Ceased
- 2023-01-20 CA CA3242074A patent/CA3242074A1/en active Pending
- 2023-01-20 AR ARP230100132A patent/AR128310A1/es unknown
- 2023-01-20 MX MX2024008840A patent/MX2024008840A/es unknown
- 2023-01-20 KR KR1020247023725A patent/KR20240136972A/ko active Pending
- 2023-01-20 JP JP2024540933A patent/JP7714811B2/ja active Active
- 2023-01-20 CN CN202380016422.5A patent/CN119053610A/zh active Pending
- 2023-01-20 IL IL312709A patent/IL312709A/en unknown
- 2023-01-20 EP EP23707582.5A patent/EP4466273A1/en active Pending
-
2024
- 2024-03-05 US US18/595,898 patent/US20250066388A1/en not_active Abandoned
- 2024-07-15 CO CONC2024/0009334A patent/CO2024009334A2/es unknown
-
2025
- 2025-07-02 US US19/258,642 patent/US20260028356A1/en active Pending
- 2025-07-15 JP JP2025118767A patent/JP2025160251A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240136972A (ko) | 2024-09-19 |
| WO2023141536A1 (en) | 2023-07-27 |
| US11964990B2 (en) | 2024-04-23 |
| JP7714811B2 (ja) | 2025-07-29 |
| IL312709A (en) | 2024-07-01 |
| CN119053610A (zh) | 2024-11-29 |
| CO2024009334A2 (es) | 2024-07-18 |
| JP2025160251A (ja) | 2025-10-22 |
| AR128310A1 (es) | 2024-04-17 |
| US20250066388A1 (en) | 2025-02-27 |
| US20260028356A1 (en) | 2026-01-29 |
| EP4466273A1 (en) | 2024-11-27 |
| JP2025504382A (ja) | 2025-02-12 |
| MX2024008840A (es) | 2024-07-25 |
| TW202340210A (zh) | 2023-10-16 |
| US20230234971A1 (en) | 2023-07-27 |
| CA3242074A1 (en) | 2023-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260028356A1 (en) | 1,3,4,7-tetrahydro-2h-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | |
| EP3341367B1 (en) | Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators | |
| JP7784041B2 (ja) | がんの治療のためのｅｎｔ阻害剤としての大環状ジアミン誘導体、及びそれとアデノシン受容体拮抗薬との組合せ | |
| EP3484881B1 (en) | Bicyclic heteroaryl substituted compounds | |
| US20250270210A1 (en) | BCL-2 Inhibitor | |
| TW201920194A (zh) | 大環ｍｃｌ-１抑制劑及使用方法 | |
| CN114478485B (zh) | 作为vanin抑制剂的杂芳族化合物 | |
| CN112533598A (zh) | 大环mcl-1抑制剂和使用方法 | |
| EA032356B1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств | |
| WO2016022448A1 (en) | Antidiabetic bicyclic compounds | |
| JPWO2021047622A5 (https=) | ||
| EA025840B1 (ru) | Производные пиразина в качестве агонистов каннабиноидного рецептора 2 | |
| CA3177058A1 (en) | Aryl piperidines as monoacylglycerol lipase modulators | |
| WO2015172732A1 (zh) | 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物 | |
| UA123071C2 (uk) | ІНГІБІТОРИ ДОФАМІН-<font face="Symbol">b</font>-ГІДРОКСИЛАЗИ | |
| CN104507915A (zh) | 环烷基醚化合物及其作为bace抑制剂的用途 | |
| JP7825294B2 (ja) | Ｎｌｒｐ３阻害剤としての化合物 | |
| ES2634693T3 (es) | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil¿oxazol como agonistas del receptor de ALX | |
| JP2020531510A (ja) | ボロン酸誘導体 | |
| EP1856032A1 (en) | Heterocyclic-substituted alkanamides useful as renin inhibitors | |
| WO2016025363A1 (en) | Bryostatin analogs and use thereof as antiviral agents | |
| JP7080900B2 (ja) | Ｐｉ３－キナーゼ活性の阻害剤としてのオキセピノピラゾール誘導体 | |
| IL324629A (en) | Cyclin inhibitors | |
| KR20260010406A (ko) | Irak4의 리간드 지정 분해제로서의 헤테로아릴 화합물 | |
| CN118974059A (zh) | 囊性纤维化跨膜传导调控因子的调节剂 |